来迪派韦联合索磷布韦治疗HCV/HBV合并感染患者的疗效
这项在台湾开展的多中心、开放标签3b期研究纳入111例HCV/HBV合并感染患者,给予来迪派韦90 mg联合索磷布韦400 mg每日一次共12周,全部111例(100%)获得持续病毒学应答;多数患者出现HBV DNA升高但不伴症状,5例HBV DNA升高伴丙氨酸氨基转移酶超过正常上限2倍,其中3例启动HBV治疗。
要点
- 来迪派韦联合索磷布韦治疗12周,111例HCV/HBV合并感染患者全部(100%)获得持续病毒学应答。
- 基线HBV DNA低于20 IU/mL的37例中31例(84%)在治疗后12周内至少1次可定量HBV DNA。
- 基线HBV DNA≥20 IU/mL的74例中39例(53%)在治疗后12周内HBV DNA升高超过1 log10 IU/mL。
核心结论
- 在这项前瞻性研究中,来迪派韦联合索磷布韦治疗12周使HCV/HBV合并感染患者100%获得持续病毒学应答。
- 多数患者出现HBV DNA水平升高但不伴体征或症状。
研究设计与样本
- 3b期、多中心、开放标签研究,在台湾纳入111例HCV/HBV合并感染患者。
- 61%为HCV基因1型,39%为HCV基因2型;62%为女性,16%有代偿性肝硬化。
- 除1例筛查时HBsAg阳性而基线时HBsAg阴性外,其余均为HBsAg阳性。
- 33%既往接受过HCV治疗,5%既往接受过HBV治疗,研究开始时无患者正在接受HBV治疗。
- 所有患者接受来迪派韦90 mg与索磷布韦400 mg固定剂量复方制剂,每日一次,共12周;主要终点为治疗结束后12周的持续病毒学应答。
主要发现
- 全部111例患者(100%)获得持续病毒学应答。
- 基线HBV DNA低于20 IU/mL的37例中,31例(84%)在治疗后12周内至少1次可定量HBV DNA。
- 基线HBV DNA≥20 IU/mL的74例中,39例(53%)在治疗后12周内HBV DNA升高超过1 log10 IU/mL。
- 共5例在治疗后12周内HBV DNA升高并伴丙氨酸氨基转移酶超过正常上限2倍,其中3例启动HBV治疗。
- 另有1例自第8周起HBV再激活并在治疗后48周伴丙氨酸氨基转移酶超过正常上限2倍,于治疗后53周开始治疗,该患者有与HBV再激活相关的临床体征和症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There have been reports of reactivation of hepatitis B virus (HBV) infection during treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents. We performed a prospective study of risks and outcomes of HCV infection treatment with ledipasvir and sofosbuvir in patients with HBV infection. METHODS: We performed a phase 3b, multicenter, open-label study in Taiwan of 111 patients with HCV infection (61% HCV genotype 1, 39% HCV genotype 2 infection; 62% women, 16% with compensated cirrhosis) along with HBV infection. All but 1 were positive for the hepatitis B surface antigen (HBsAg); 1 patient who was HBsAg-positive at screening was found to be HBsAg-negative at baseline. Overall, 33% of participants had received prior treatment for HCV and 5% had previously been treated for HBV; no patient was on HBV therapy at the start of the study. All patients received a fixed-dose combination of 90 mg of the HCV NS5A inhibitor ledipasvir with 400 mg of the NS5B nucleotide analogue inhibitor sofosbuvir, once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks after the end of therapy. RESULTS: All 111 patients (100%) achieved a sustained virologic response. Of the 37 patients with baseline HBV DNA below 20 IU/mL, 31 (84%) had at least 1 episode of quantifiable HBV DNA through posttreatment week 12. Of the 74 patients with baseline HBV DNA levels of 20 IU/mL or more, 39 (53%) had increases of HBV DNA greater than 1 log10 IU/mL through posttreatment week 12. Overall, 5 patients had increased levels of HBV DNA concomitant with a level of alanine aminotransferase >2 times the upper limit of normal through posttreatment week 12. Of these, 3 patients started HBV treatment. In addition, 1 patient with HBV reactivation since week 8 and concomitant alanine aminotransferase elevation >2 times upper limit of normal at posttreatment week 48 started treatment at posttreatment week 53. This patient had clinical signs and symptoms associated with HBV reactivation. The most common adverse events were headache, upper respiratory infection, and fatigue. CONCLUSIONS: In a prospective study, the combination of ledipasvir and sofosbuvir for 12 weeks produced a sustained virologic response in 100% of patients with HCV infection who were coinfected with HBV. Most patients had an increase in level of HBV DNA not associated with signs or symptoms. ClinicalTrials.gov no: NCT02613871.
引用
- Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology. 2017. PMID: 29174546. doi:10.1053/j.gastro.2017.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。